- Home
- DXYZ vs XOMA Comparison
DXYZ vs XOMA Comparison
Compare DXYZ & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXYZ
- XOMA
- Stock Information
- Founded
- DXYZ N/A
- XOMA 1981
- Country
- DXYZ
- XOMA United States
- Employees
- DXYZ N/A
- XOMA 13
- Industry
- DXYZ
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- DXYZ
- XOMA Health Care
- Exchange
- DXYZ Nasdaq
- XOMA Nasdaq
- Market Cap
- DXYZ 313.1M
- XOMA 457.6M
- IPO Year
- DXYZ 2024
- XOMA N/A
- Fundamental
- Price
- DXYZ $26.39
- XOMA $37.09
- Analyst Decision
- DXYZ
- XOMA Strong Buy
- Analyst Count
- DXYZ 0
- XOMA 2
- Target Price
- DXYZ N/A
- XOMA $69.50
- AVG Volume (30 Days)
- DXYZ N/A
- XOMA 52.3K
- Earning Date
- DXYZ N/A
- XOMA 11-06-2025
- Dividend Yield
- DXYZ N/A
- XOMA N/A
- EPS Growth
- DXYZ N/A
- XOMA N/A
- EPS
- DXYZ N/A
- XOMA N/A
- Revenue
- DXYZ N/A
- XOMA $44,952,000.00
- Revenue This Year
- DXYZ N/A
- XOMA $82.30
- Revenue Next Year
- DXYZ N/A
- XOMA $12.59
- P/E Ratio
- DXYZ N/A
- XOMA N/A
- Revenue Growth
- DXYZ N/A
- XOMA 194.98
- 52 Week Low
- DXYZ N/A
- XOMA $18.35
- 52 Week High
- DXYZ N/A
- XOMA $38.34
- Technical
- Relative Strength Index (RSI)
- DXYZ 39.32
- XOMA 69.05
- Support Level
- DXYZ $26.00
- XOMA $33.59
- Resistance Level
- DXYZ $27.95
- XOMA $38.00
- Average True Range (ATR)
- DXYZ 1.03
- XOMA 1.59
- MACD
- DXYZ 0.18
- XOMA 0.07
- Stochastic Oscillator
- DXYZ 18.30
- XOMA 82.87
About DXYZ Destiny Tech100 Inc. Common Stock
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.